Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.
Overview
publication date
- November 2, 2020
published in
- JCO precision oncology Journal
Identity
PubMed Central ID
- PMC7713518
Scopus Document Identifier
- 85096865220
Digital Object Identifier (DOI)
- 10.1200/PO.20.00271
PubMed ID
- 33283131
Additional Document Info
has global citation frequency
volume
- 4